This is consistent with evidence from the study by Humrich et al., who showed that Ld-IL-2 therapy significantly increased CD4^+ CD25^hi CD127^lo Tregs and improved their suppressive capacity in refractory SLE patients [13]. The gene discussed is IL2; the disease is systemic lupus erythematosus.